NCT06818136
Bladder EpiCheck European Haematuria Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Primary completion pushed from Aug 2026 to Dec 2026
- Study completion pushed from Dec 2026 to Jun 2027
- Minor Enrollment target: 600 to 800
- Study sites: 2 to 5
- Primary completion date: Feb 2026 to Aug 2026
- Study completion date: Apr 2026 to Dec 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Start date changed from estimate of Apr 2025 to Jun 20, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The sensitivity and specificity of Bladder EpiCheck to detect primary urothelial carcinoma
Timeframe: urothelial carcinoma detected within 6 months of enrolment, by the standard of care haematuria work-up
Secondary (2)
Non-inferiority of Bladder EpiCheck overall sensitivity vs. cytology in detection of primary urothelial carcinoma
Non-inferiority of Bladder EpiCheck specificity vs. cytology in detection of primary urothelial carcinoma
Arms and interventions
aged ≥ 45 years with haematuria scheduled for cystoscopy, for suspicion of urothelial carcinoma
Adult participants aged ≥ 45 years presenting with haematuria in the past 6 months, scheduled to undergo haematuria workup, including cystoscopy, for suspicion of urothelial carcinoma.
Diagnostic tests: Bladder EpiCheck
Sites
7 sites in 1 country